Zyprexa news from FiercePharma
NewsUnder pharma earnings, basic problems
You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
Judge wary of certifying Zyprexa classes
Score one for Eli Lilly in federal court. A district judge says he probably won't give class-action status to patients and insurers who paid for Zyprexa for FDA-approved uses. And he doesn't expect Read more...
If J&J misled FDA, can patients sue?
Drug companies appear to be close to gaining a long-coveted prize: A shield against patient lawsuits. The Bush administration has been Read more...
Forbes to Big Pharma: Fess up
Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. If the controversial Enhance study had proven Vytorin Read more...
ALSO NOTED: Pre-emption fears helped spur Zyprexa deal; U.K. implant makers charge U.S. market;
> Scratching your head over the Zyprexa settlement in Alaska? Apparently, the prospect of a Supreme Court ruling that might sweep away state pharma suits helped spur the agreement. Read more...
Lilly, Alaska settle Zyprexa suit for $15M
One down, more than a dozen to go. Eli Lilly agreed to settle with the State of Alaska, promising Read more...
Judge: FDA can't police drugs alone
As Eli Lilly went up to bat in the big Zyprexa trial in Alaska, Read more...
Did Lilly chief support off-label promos?
You can bet incoming Eli Lilly CEO John Lechleiter (photo) spat out his Cheerios when he read the New York Times Read more...
| Press ReleasesPRESS RELEASE: Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa as the First-Line Antipsychotics of Choice in the Treatment for Schizophrenia Bristol Meyers Squibb/Otsuka Read more... |
Get more Zyprexa coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight